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1 Introduction
Calpain (Clan CA, family C02, EC 3.4.22.17) comprises a
family of cysteine proteases whose activity is dependent
on an increase in cytosolic Ca2+ [1–3]. In the human
genome, 14 genes encode calpain homologues. They are
categorized into two groups, ubiquitous and tissue-spe-
cific calpains, based on their expression profiles. Because
the two ubiquitous calpains, μ- and m-calpain, were the
first calpains to be identified, the term ‘conventional cal-
pains’, was applied to them. They are heterodimers and
consist of large catalytic subunits (CAPN1 and CAPN2, or
μCL and mCL) and smaller regulatory subunits (30K sub-
units). As protease enzymes, the μ- and m-calpains have
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common substrate and inhibitor specificities but differ in
their Ca2+ dependence and preference for peptide sub-
strates over protein substrates. Unexpectedly, it was
shown that a lack of m-calpain, but not μ-calpain, causes
embryonic lethality [4–7]. Therefore, despite an activation
requirement of Ca2+ concentrations of several hundred
millimolar, the implementability of which is yet to be
demonstrated in vivo, it has been proposed that m-cal-
pain plays a fundamental role in the maintenance of life
and/or is critical for early development, and is capable of
compensating for some μ-calpain functions.
Under normal cellular conditions, calpain activation is
a tightly regulated process coupled to the homeostasis of
the intracelluar free calcium concentration ([Ca2+]i). Cal-
pain is activated when [Ca2+]i concentrations increase.
The cleavage of target proteins by calpain often alters
their functions, activities, and/or structures, modulating
many cellular functions. Therefore, identification of cal-
pain substrates and elucidation of the effects of calpain
proteolysis on their functions is important for elucidation
of the molecular mechanisms of biological phenomena
that involve calpain. As calpain is important for normal
cell function, many pathological conditions are associat-
ed with over-activation of calpain consequent to loss of
[Ca2+]i homeostasis. For example, in brain ischemia, neu-
ronal cell death, cardiac dysfunction, and muscular dys-
trophies, excessive proteolysis of substrates by calpain,
which is not the primary cause of these pathological
states, further compromises cellular functions and aggra-
vates symptoms [8–13]. These conditions indicate that
calpain is a promising target for strategies aimed at ame-
liorating and/or retarding the progression of the symp-
toms of these diseases [14–16].
On the other hand, only one human pathological con-
dition has been shown to result from genetic loss of cal-
pain protease activity. Limb-girdle muscular dystrophy
type 2A (LGMD2A) is caused by a loss of the protease ac-
tivity of the skeletal-muscle-specific calpain p94/calpain
3, which is caused by a pathogenic mutation of the p94
gene, CAPN3 [17, 18]. Studies on the properties of the p94
molecule and on specific cellular events involving p94,
such as apoptosis and myogenic differentiation, have
contributed to current understanding of the p94 molecule,
and several proteins have been identified as substrates of
p94 [19–21]. Although the role that the p94 molecule plays
in vivo is not fully understood, it is possible that the dys-
trophic muscle phenotype observed in LGMD2A is the re-
sult of accumulated losses in cellular responses to various
physiological perturbations because p94 lacks its pro-
tease activity. An alternative ubiquitous promoter of
CAPN3 was recently identified and the expression of sev-
eral p94 variants in various organs, including the brain,
has been reported [22–24], suggesting that p94 is impor-
tant for tissues other than skeletal muscles.
The primary structure of p94 is very similar to that of
the catalytic subunits of the μ- and m-calpains; however,
several unique and enigmatic properties distinguish p94
from the conventional calpains. Most significantly, p94
exhibits very rapid autoproteolytic activity in all protein
expression systems examined to date [25, 26]. Although
native p94 protein is abundant in protein preparations
made from skeletal muscles, it disappears as a result of
autolysis during purification, suggesting that a skeletal-
muscle-specific mechanism for stabilizing p94 prevails in
vivo[27]. As a consequence of its autolysis, analysis of p94
protease activity using standard methodologies is diffi-
cult. To elucidate the etiology of LGMD2A, data are re-
quired on the identity of the substrates of p94 and on
when and how they are proteolyzed. As our previous
study [28] demonstrated that p94 has substrate specifici-
ties very similar to those of the μ- and m-calpains, studies
on p94 substrates would contribute to the understanding
of brain-specific diseases that involve the conventional
calpains.
One of the advantages of using p94 is that Ca2+ stim-
ulation is not necessary for its activation; the convention-
al calpains have to be activated by an increase of [Ca2+]i
concentrations provoked by molecules such as Ca2+
ionophores, the presence of which affects the entire cell.
Using COS7 cells transfected with a p94 expression vec-
tor and Western blot analyses, we previously detected
proteolysis of several proteins, suggesting that p94 prote-
olytic activity is readily exerted and that the proteins
identified are potential in vivo p94 substrates [17]. Con-
sidering that more than 100 proteins have been identified
as in vitro substrates of conventional calpains [1], many
p94 substrates have not yet been identified because of the
constraints of conventional detection methods.
In this study, quantitative proteomic analysis was per-
formed using the COS7 expression system and the
iTRAQTM method [29–31]. The isobaric tagging of pep-
tides using multiplexed iTRAQTM reagents prior to MS al-
lows identification and quantification of the same peptide
derived from different origins, e.g., cancer cells at differ-
ent malignant states. Proteases represent one of the most
direct effectors on the amount of substrate proteins.
Therefore, quantitative as well as comprehensive pro-
teomic analysis is promising for identification of novel
protease substrates, although few reports have been pub-
lished [32]. Several proteins were identified as potential
p94 substrates; these included known substrates of con-
ventional calpains, which supports that p94 and the con-
ventional calpains have common substrate specificities,
an indication from our previous study [28]. By Western
blot analysis, fodrin, one of the few in vivo substrates of
conventional calpains that is proteolyzed during is-
chemia, was readily detected to be proteolyzed by p94.
The net abundance of fodrin determined by its trypsin-di-
gested product did not decrease in concert with the de-
crease in unproteolyzed fodrin levels, suggesting that the
proteolytic product by p94 is relatively stable. These data
highlight the usefulness of proteomic analysis as a com-
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plement to conventional analytical methods for thorough
analysis of proteolytic events elicited by calpain.
2 Materials and methods
2.1 Protein expression in COS7 cells and iTRAQTM reagent
labeling
Cell culture and transfection (electroporation) methods for
COS7 cells, cDNA constructs for expressing human p94s,
wild-type (WT) and a protease-inactive p94:C129S mu-
tant (CS) were described previously [27]. At 72 h after
electroporation, harvested cells (ca. 0.5 × 107–1.0 × 107
cells) were lysed in 200 μL 20 mM triethylammonium bi-
carbonate (Nacalai Tesque, Japan) by sonication. The cell
lysate was centrifuged at 18 000 × g for 20 min at 4°C, the
supernatant was removed, and protein concentration was
quantified using the DC protein assay (Bio-Rad, Japan).
From cells expressing either WT or CS, 72 μg protein
was prepared and diluted to 20 μL using 0.5 M triethy-
lammonium bicarbonate containing 0.1% SDS. Protein
was reduced, alkylated, and trypsin-digested prior to labe-
ling with iTRAQTMreagent according to the manufacturer’s
protocol (ABI, USA). The digested protein prepared from
each cell was divided into two portions for labeling with
iTRAQTM 114 and 116 (WT) or 115 and 117 (CS) (Fig. 1A).
2.2 Peptide fractionation for 2-D LC-MALDI-MS/MS analysis
2-D peptide fractionation was performed on a DiNa Direct
Nano-flow LC system equipped with a MALDI-plate spot-
ter (DiNa MaP; KYA Tech, Japan ) using a strong cation
exchange (SCX) column [HiQ Sil SCX, 0.5 mm inside di-
ameter (id) × 35 mm], a reverse-phase (RP) trap column
(HiQ Sil C18-3, 0.8 mm id × 3 mm), and an RP analytical
column (HiQ Sil C18-3, 0.15 mm id ×50 mm). Labeled pep-
tides were pooled, diluted with 2.5 volumes of MilliQ wa-
ter, and acidified to pH 3.0 using 1 M phosphoric acid.
Half of the preparation was used per injection. Peptides
trapped on the SCX column were eluted using a gradient
program consisting of eight linear segments: 0–5% sol-
vent B in solvent A (solvent A: 0.1% formic acid, 2% ace-
tonitrile; solvent B: 500 mM ammonium formate buffer 
pH 3.0, 2% acetonitrile) for 10 min, followed by 5–10%,
10–15%, 15–20%, 20–30%, 30–50%, 50–100%, and 100%
solvent B in solvent A, each for 10 min at a flow rate of
4000 nL/min. Eluent from each gradient segment was
pooled and injected into the trap column and then the an-
alytical column using a gradient of 0–50% solvent D in sol-
vent C over 60 min (solvent C: 0.1% TFA, 2% acetonitrile;
solvent D: 0.1% TFA, 70% acetonitrile) and 50–100% sol-
vent D in solvent C for 10 min at a flow rate of 300 nL/min.
The RP column effluent was mixed with the MALDI ma-
trix solution (4 mg/mL α-cyano-4-hydroxycinnamic acid
dissolved in 70% acetonitrile containing 0.1% TFA and 
80 μg/mL dibasic ammonium citrate) flowing at a rate of
1400 nL/min at the outlet, and spotted directly onto the
ABI 4800 MALDI-plates in a 24 × 16 array at a frequency
of two spots per minute. Four MALDI-plates correspon-
ding to eight gradient segments in SCX chromatography
(2736 spots) were analyzed.
Biotechnol. J. 2007, 2, 565–576 www.biotechnology-journal.com
Figure 1.Proteomic analysis of COS7 cells expressing p94. (A) Overview of experimental design. (B) Number of peptides/proteins identified in the 2-D LC-
MALDI analysis. More than half the identified proteins were represented by a single peptide. Of the proteins identified, 11% had more than six peptides;
these included vimentin, several different heat shock proteins, and cytoplasmic actins, which are known to be abundant.
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2.3 MS and database search
Mass spectra were acquired in batch mode using an
ABI4800 Proteomics Analyzer operated by 4000 Series Ex-
plorer Software (V. 3.5; ABI). Measurement conditions
were set according to the values recommended by the
manufacturer with some modification; the maximum
number of peaks for MS/MS acquisition per spot, the S/N
filter, and spot-to-spot tolerance were set at 10, 100 or 150,
and 200 ppm, respectively. For each MALDI plate, the in-
strument was set to scan mass spectra between 800 and
4000 m/z. Two or three cycles of non-redundant MS/MS
scans were performed.
All MS/MS spectra were combined and a single data-
base search was performed against primate protein se-
quences in the Swiss-Prot database using GPS Explorer
software (V. 3.6; ABI) and MASCOT as a search algorithm.
Search parameters included modifications by iTRAQTMat
N-terminal residues and internal K and Y residues, me-
thylmethane thiosulphation of cysteine, and one missed
cleavage; the maximum peptide rank was set at 2, and the
minimum ion score was set at 85%.
2.4 Data analysis
Relative quantification of identical peptides labeled with
four different iTRAQTMtags was performed on the MS/MS
peak list by comparing the areas of four signature peaks
at 114, 115, 116, and 117 m/z. Values were normalized us-
ing the sum of values obtained for all tagged peptide pairs
in the sample; data sets were imported into MS-Excel for
further analysis. Relative changes in the abundance of in-
dividual peptides were defined as follows [S11x (x = 4, 5, 6,
or 7) and R represent normalized iTRAQTM signal values
and the ratio, respectively]: if R ≥ 1 (0 < R < 1) for any com-
bination of S115 or S117/S114 or S116, the minimum (the in-
verse of the maximum) was adopted, representing a fold
increase (decrease); otherwise, relative change was ex-
pressed as 1.0, meaning that detected changes were not
consistent within internally replicated comparisons. Pep-
tides with relative change values greater than 1.10 were
subjected to manual inspection of the quality of their
MS/MS spectra. MS/MS spectra without a complete set of
four measurable iTRAQTM tags were excluded from the
analysis.
2.5 Western blotting and antibodies
Cell lysates prepared as described in Section 2.1 were
separated by SDS-PAGE and transferred to PVDF mem-
branes (Millipore, Japan) as previously described. The
membranes were probed with a series of primary anti-
bodies in combination with appropriate secondary anti-
bodies conjugated to horseradish peroxidase (POD), and
were visualized using POD immunostaining kit (Wako,
Japan). The primary antibodies were: p94-specific anti-
IS2 antibody, which was raised in goats [26–28], goat anti-
eEF2 antibody (sc-13004, Santa-Cruz Biotech), mouse
anti-β-actin antibody (A1978, Sigma, MO, USA), mouse
anti-vimentin antibody (V6630, Sigma), goat anti-filamin
A antibody (F2762, Sigma), mouse anti-fodrin mAb (clone
AA6, Biohit, Finland), and mouse anti-annexin A1 and A2
antibodies (clones 29 and 5, respectively, BD Biosciences,
USA). A polyclonal anti-GMMPR antiserum, which
specifically detects the 150K fodrin fragment proteolyzed
by calpain, was elicited using rabbits as previously de-
scribed [33].
2.6 In vitro translation
In vitro translation experiments were performed as previ-
ously described using a rabbit reticulocyte lysate in vitro
translation kit (DuPont-NEN, UK) and L-[35S]Met in the
presence or absence of 380 μg/mL leupeptin and E-64 as
previously described [26]. Briefly, the translation reaction
mixture was mixed directly with an equal volume of SDS-
PAGE sample buffer at specified times, and subjected to
SDS-PAGE. Gels were dried, exposed to Fujix (Japan) im-
aging plates and X-ray films, and measured and analyzed
using a Fujix Model BAS2000 Bioimage Analyzer.
3 Results and discussion
In COS7 cells, overexpressed p94 disappears very rapidly
because of its autolytic activity (see below) [26] and si-
multaneously causes specific proteolysis of other proteins
such as calpastatin and fodrin [17]. Calpastatin is a spe-
cific endogenous inhibitor of conventional calpains and
fodrin is an in vivo substrate of conventional calpains. To
identify proteins targeted by p94 protease activity, quan-
titative proteomic analysis of COS7 cells expressing ei-
ther p94 WT or CS was performed using the iTRAQTM
technique and 2-D LC-MALDI-MS/MS analysis. Equal
amounts of trypsin-digested peptides from each sample
were individually labeled using one of four iTRAQTM tags,
which are specifically incorporated into free amine
groups. As these tags are isobaric, have the same mass,
and are chemically similar to one another, identical pep-
tides originating from different types of cells were ex-
pected to be present in the same fractions throughout the
LC separation procedure [29, 30]. Fragmentation of these
peptides by MS/MS analysis simultaneously yields four
specific peaks derived from each iTRAQTM tag at 114,
115, 116, and 117 m/z; the intensity of the signal corre-
sponds to the amount of peptides labeled with each tag.
Thus, the relative abundance of identical peptides in dif-
ferent populations of cells, either WT or CS, was deter-
mined. Consequently, the amount of the parent protein
from which the peptides were derived can be quantified.
Integration of this information facilitates proteomic eval-
uation of the effect of p94 protease activity on intracellu-
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lar proteins of culture cells in which conditions close to, if
not equal to, that of the in vivo situation prevail. Proteins
whose cellular abundance has been altered by p94 pro-
tease activity are expected to yield R values greater
(down-regulated) or smaller (up-regulated) than 1 (no
change), where R represents the ratio of iTRAQTM signals
for CS/WT. The comparison between WT and CS samples
was performed using four R values (Fig. 1A).
Using a total of 144 μg protein extracted from COS7
cells (36 μg labeled with each iTRAQTM reagent), 2926
peptides, of which 1610 were unique, were identified
from 5197 MS/MS spectra. Based on MS spectra of elution
profiles of 2-D LC, visual inspection of several MS/MS
spectra, and statistical assessment of iTRAQTM signals
(Figs. 2A and B), it was concluded that the experimental
procedure yielded a reasonable amount of MS/MS data
with reliability, and further analysis of the proteome of
COS7 cells expressing p94 was performed. The identified
peptides corresponded to 593 proteins, more than half of
which were represented by a single unique peptide (Fig.
1B). As expected, abundant proteins were associated
with many different peptides: vimentin, 23 peptides;
HSP90β, 20 peptides; and β-actin, 14 peptides. Five pep-
tides, 4 of which were unique, were identified for p94,
which illustrates the difference between the sensitivity of
this approach and that of other conventional methods
such as Western blot analysis (see subsequent results).
Distributions of modified signal ratios of iTRAQTM 116
(WT-2) to 114 (WT-1) and those of 115 (CS-1) to 114 (WT-1)
were compared to each other. Replicate WT samples
showed that signal measurement was reproducible
(mean = –0.0090, SD = 0.2359) (Fig. 2D). Although most
peptides were expressed at similar levels in WT and CS
samples, the SD was larger for this pair, indicating that
peptides whose abundance differed between WT and CS
were present (Fig. 2C). These properties are also evident
in the scatter plots of iTRAQTM signals for each of WT-WT
and WT-CS pairs (Figs. 3A and B). The reproducibility of
data for WT samples was in good accordance with the ex-
pected accuracy of this method [34], while replicated
Biotechnol. J. 2007, 2, 565–576 www.biotechnology-journal.com
Figure 2.Statistical profiles of LC-MALDI analysis. 
(A, B) Error distribution of masses in Da (A) or ppm (B)
between observed and calculated/theoretical molecular
masses of 2801 identified MS/MS spectra out of 5197
spectra. Dotted lines indicate means and ranges for one
and two SDs. (C, D) Modified ratios of iTRAQTM signals
of 115 (CS-1) to 114 (WT-1) (C) or 116 (WT-2) to 114
(WT-1) (D). Values of ratios were modified as follows:
Modified ratio = R – 1 (if R ≥ 1), 1/R – 1 (if 1 > R > 0),
where R = iTRAQTM signal ratio.
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analysis of CS samples resulted in slightly poorer repro-
ducibility than that of WT (Figs. 3C and D). To minimize
false positives, only peptides for which the iTRAQTM sig-
nal ratios (Rs) of all possible combinations of WT and CS
samples,  i.e., 115/114, 117/114, 115/116, and 117/116,
changed in identical directions were considered for fur-
ther analysis.
Extracted peptides were sorted according to the rela-
tive change in abundance (= Rmin if R ≥ 1; = 1/Rmax, if
1>R> 0, where R = signal ratio of 115 or 117 to 114 or 116)
(Table 1). In several studies conducted using the iTRAQTM
methodology, differences greater than 1.2-fold have been
suggested to be considered significant [35]. In the pres-
ent analysis, where a difference is represented by the
minimal fold change, 1.10 was used as an arbitrary cut-off
point. MS/MS spectra of these peptides were inspected
visually. Proteins represented by peptides with reliable
MS/MS spectra and whose signal ratios were decreased
by WT p94 expression are listed in Table 2. Representa-
tive images of MS/MS spectra for amino acid sequencing
and iTRAQTM signal quantification are shown in Fig. 4.
Among the proteins listed in Table 2, p94 was ranked
as the protein with the greatest decrease (averaged Rmin
for peptides = 3.024, n = 5) (Fig. 4G). This is the first quan-
titative demonstration that the best substrate for p94 is
p94 itself. The data also illustrate that the meaning of a
quantitative change of a protein determined by the abun-
dance of peptide derivatives is different from that detect-
ed by other methods such as Western blot analysis. An au-
tolytic decrease in the full-length p94 in COS7 cells was
detected by Western blot analysis, which showed that the
amount of WT (addition of 94 kDa, 55 kDa and other small-
er bands) is less than 1/100 of that of CS (Fig. 5A “p94”).
On the other hand, the quantity of WT p94 was ca. 1/3 of
that of CS at the peptide level when measured by the
iTRAQTM method (Table 2, Fig. 5D). All five (four unique)
peptides (Fig. 5C “p94”) detected for p94 decreased in WT
samples to a similar extent. This large difference of de-
tected relative WT quantity suggests that most of identi-
fied peptides for WT p94 by the iTRAQTM method are de-
rived from extensively autolyzed fragments of p94 that
could not be detected by Western blot analysis due to
small molecular mass and heterogeneity of the autolyzed
fragments (Fig. 5D). Similar decreases of all five peptides
detected for WT p94 indicate that upon autolysis, differ-
ent autolyzed fragments of WT p94 concurrently become
more susceptible to subsequent degradation than unau-
tolyzed p94 protein.
Figure 3.Scatter plots of iTRAQTM signals
(absolute values) between 114 (WT-1) and
115 (CS-1) (A), 114 (WT-1) and 116 (WT-2)
(B), 115 (CS-1) and 117 (CS-2) (C), and 114
(WT-1) and 117 (CS-2) (D). Ranges of
twofold and fourfold, one-half, and one-
quarter are indicated by dotted lines. R2,
correlation coefficient.
Table 1. Relative abundance quantified by iTRAQTM analysis
Increased by p94  Decreased by  Total
(WT > CS) p94 (WT < CS)
Relative change >1.25 >1.15 >1.10 1.10< 1.15< 1.25<
No. of peptides 22 48 76 80 52 29 307
No. of proteinsa) 20 40 61 59 44 22 246
No. of proteinsb) 5 2 15 10 10 3 45
a) Number of proteins represented by identified peptides.
b) Number was obtained using averaged iTRAQTM ratios for all peptides repre-
senting a protein.
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Some of the proteins listed in Table 2 are previously
identified substrates for other calpains [36–39] (see the
“Previous report” column in Table 2). At present, it is not
biochemically confirmed that the identified proteins are
direct substrates for p94. Together with the previous ob-
servation, however, that p94 and the conventional cal-
pains have some common substrate specificities [28], the
present results are indicative for molecular context where
p94 directly exerts its activity. The identification of fil-
amin-A and vimentin as substrates is consistent with the
observation that ectopic expression of p94 in several dif-
ferent culture cells causes morphological defects accom-
panied by proteolysis of several cytoskeletal proteins, in-
cluding filamin-A and fodrin [40]. Western blot analysis
detected a slight decrease in filamin-A and vimentin in
WT samples, while the decrease in annexin A1 or A2 was
less obvious (Fig. 5A). The proteins listed in Table 2 also
include components of translation machinery (eEF1α-1
and -2, eEF-2 and initiation factor 3). eEF-1α is prote-
olyzed by drosophila calpain [36], and eEF-2, which was
shown to be related to p94, was decreased in WT samples
according to Western blot analysis (Fig. 5A). These results
strongly suggest that there is interaction between p94
and the translation machinery, which was further con-
firmed by the following experiment. When p94 was trans-
lated in vitro using the rabbit reticulocyte lysate system,
p94 exhibited co-translational autolytic activity during
the initial phase; the signal intensity for the full-length
translated product was ca. 1/10 lower than that of the μ-
calpain large subunit (μCL) translated in the same system
(Fig. 6A, 0–20 min). The intensity of the 94-kDa band as
well as that of other smaller bands reached a local maxi-
mum at about 20 min from the start of translation and then
decayed (Fig. 6B). In contrast, μCL exhibited an almost
linear increase in 80-kDa band intensity regardless of the
presence of high concentrations of the Ser/Cys-protease
inhibitors, leupeptin and E64 (Fig. 6, + or –inh.). If p94 only
had autolytic activity, the amount of p94 would not have
Biotechnol. J. 2007, 2, 565–576 www.biotechnology-journal.com
Figure 4.Examples of MS/MS spectra that exhibited
significant differences in iTRAQTM signal ratios. (A)
MS/MS spectrum of precursor ion of 3410.5859, which
was identified as elongation factor 2 with ion score 72
and I.C. 99.9% [calculated mass is 3410.5439, error =
0.0420 (12 ppm)]. Representative peaks are shown and
calculated masses are indicated in parentheses. The
predicted amino acid sequence is shown in the box,
which corresponds to residue 801–829 of human EF2
with N-terminal iTRAQTM and Cys-MMTS modification
(indicated by *). The small square around m/z = 100 is
the area magnified in (B). (B) Magnification of iTRAQTM
signals shown in (A). (C–G) Magnified iTRAQTM signals
of MS/MS spectrum (data not shown) identified as fil-
amin A (C), annexin A1 (D), annexin A2 (E), vimentin
(F), and p94 (G). The predicted peptide corresponds to
residues 309–330 of human filamin A, 29–52 of human
annexin A1, 179–195 of human annexin A2, 36–49 of
human vimentin, and 733–748 of human p94.
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decayed, but would have asymptotically approached a
plateau at which protein synthesis would have been in
balance with autolytic degradation. Thus, the observed
local maximum with subsequent decay indicates that
synthesis of p94 protein gradually decreased, which was
probably due to proteolysis of the translation machinery
by p94 as shown in iTRAQTM experiments. These data
strongly suggest that p94 is involved in regulation of the
eukaryote protein synthesis system, as is the case for the
conventional calpains [36].
Other proteins identified as possible p94 substrates
revealed novel aspects of the function of p94. Fructose
bisphosphate aldolase A, glyceraldehyde-3-phosphate
(GAP) dehydrogenase, and triosephosphate isomerase
catalyze successive reactions (fructose bisphosphate →
dihydroxy acetonephosphate + GAP → 2GAP → 1,3-bis-
phosphoglyceric acid) in the glycolytic system, which is
highly developed in skeletal muscle. Another proteomic
study using 2-DE and transgenic mice overexpressing
p94 identified other glycolytic enzymes as p94 substrates
in skeletal muscle [41], suggesting a role for p94 in the gly-
colytic cycle [42]. Importin-7 and the annexins are in-
volved in membrane trafficking. As yeast calpain utilizes
a membrane-associated scaffold, a similar mechanism
might apply to p94 [43, 44]. Proteolysis of proteasome
regulatory subunit RPS6A by p94 may indicate that the
ubiquitin proteasome system is subject to regulation by
calpain, at least in certain cases [45]. At present, the rela-
tionship between p94 and thioredoxin is unknown. It has
yet to be clarified that cleavages of proteins identified in
this study are characterized under physiological context
as well as biochemically. It is particularly important to dis-
Biotechnol. J. 2007, 2, 565–576 www.biotechnology-journal.com
Figure 5.Comparison of identified proteins by iTRAQTM
analysis. (A) Western blot analysis of selected proteins us-
ing specific antibodies. Equal amounts of protein extract
from COS7 cells expressing either WT or CS mutant of
p94 were loaded for each blot. Closed and open arrow-
heads indicate the full-length and the autolyzed frag-
ments, respectively, detected by anti-pIS2 antibody. The
epitope region is indicated by a vertical bar in (C). AnxA1,
annexin A1; AnxA2, annexin A2. (B) 150K fragment of α-fo-
drin proteolyzed at the calpain-specific site detected by
anti-GMMPR in a protein sample from COS7 cells ex-
pressing WT but not CS (open arrowhead). The anti-fodrin
mAb detected several fragments of different sizes in addi-
tion to full-length unproteolyzed fodrin (closed arrow-
head) in both the WT and CS lanes. *, Proteolyzed 150K
fragment specific to the WT sample was also detected by
the anti-fodrin mAb, but the signal overlaps with an
unidentified band with an almost identical mobility, which
was also present in the CS sample. (C) Positional relation-
ships between previously determined proteolytic sites and
peptides identified in the present analysis. The closed ar-
rowheads indicate autolytic sites for p94 and proteolytic
sites of conventional calpains for vimentin and α-fodrin.
Closed, open, and gray circles indicate the positions in
proteins of peptides whose relative abundance were de-
creased, unchanged, or increased, respectively, in COS7
cells expressing WT p94 relative to cells expressing
p94:CS. Cys, His, and Asn indicate catalytic amino acid
residues in p94. Vertical bars indicate the positions of epi-
topes for anti-pIS2 (for p94) and anti-GMMPR (for the cal-
pain-specific 150K proteolytic fragment of fodrin). Bidirec-
tional arrows indicate the autolytic fragment of p94 and
the calpain specific proteolytic fragment of fodrin, which
correspond to the open arrowheads in (A) and (B), respec-
tively. NS, IS1, and IS2 are p94-specific insertion se-
quences. IIa and IIb comprise the calpain protease do-
main. III and IV are C2-like and 5EF-hand motif Ca2+-bind-
ing domains, respectively. 1A, 1B, and 2, coiled coil do-
mains. Sr1-19, spectrin repeat. (D) Relative quantities of
p94 protein/peptide by iTRAQTM method and Western blot analysis (WB). WT p94 amounts detected by both methods are represented as relative to those
of CS (CS = 100). Difference between CS and WT by iTRAQ ([a]) corresponds to portions in WT degraded completely (to amino acid) or at least smaller
than the length of trypsin peptides. Difference between iTRAQ and WB in WT ([b]) corresponds to portions in WT degraded partially, larger than the length
of trypsin peptides but small enough not to be detected by WB. Region [c] mainly corresponds to the 55-kDa band in WB (A, “p94”, open arrowhead).
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tinguish direct p94 substrates from those proteolyzed by
other proteases activated by overexpression of p94. The
latter case could non-physiologically happen in COS7
cells, since regulatory mechanisms for p94 activity, which
are probably effective in skeletal muscle tissues, may ab-
sent here. It should also be noticed that proteins identified
from COS7 cells could be alternatives for their counter-
parts expressed in skeletal muscle tissues. Integrated un-
derstanding of these issues would reveal physiological
behavior of p94 and its relevance to other cellular ma-
chineries with more clarity.
A notable difference between p94 and the other pro-
teins listed in Table 2 is that proteins other than p94, if
represented by multiple peptides, were only decreased by
a portion of their peptides. This is probably because the
stabilities of products generated from substrate proteins
by p94 differ. Figure 5C illustrates the distributions of the
identified peptides and the reported proteolytic sites of
p94, vimentin, and fodrin. While autolysis causes down-
regulation of p94 as a whole molecule, proteolysis of vi-
mentin would confer other properties on certain parts of
the molecule. This fits a scheme in which calpains do not
degrade target proteins, but modify the functions of tar-
gets. Consistent with this hypothesis, proteolysis of α-fo-
drin was detected in WT-expressing cells by an antibody
against a calpain-specific proteolytic product (Fig. 5B,
anti-GMMPR) [17], but not by iTRAQTM analysis. Six in-
dependent peptides from α-fodrin before and after the cal-
pain cleavage site were detected by MS/MS (Fig. 5C), es-
sentially none of which showed a change in relative abun-
dance between WT and CS samples. This indicates that
fodrin proteolysis by p94 did not change the total amount
of fodrin. This quantitative information, which is hard to
obtain solely by Western blot analysis (Fig. 5B, anti-fo-
drin), suggests that limited proteolysis of fodrin by p94
does not cause immediate degradation of fodrin frag-
ments. Although the possibility of interference at a tran-
scriptional/translational level as a consequence of p94
protease activity cannot be excluded, a more extreme
change in the abundance of target proteins as a whole
would have been observed if that were the case.
Western blot analysis showed that the decrease in
identified proteins was rather small compared with the
autolytic decrease in p94 (Fig. 5A). This was probably
caused in part by much less efficient protein proteolysis
by p94 than p94 autolysis, which could be because of that
COS7 cells but not skeletal muscle cells were used. Al-
though the expected advantage of our COS7 system is
that ectopically expressed p94WT is the only active cal-
pain present when cells were not otherwise stimulated,
the lack of stimuli to spike signaling cascades such as
[Ca2+]i regulation or cytoskeletal motility might hamper
contact between p94 and substrates and/or other mole-
cules and enhance autolytic rather than proteolytic reac-
tion.
Levels of several proteins were increased in WT sam-
ples (Table 1). This might indicate that proteolysis by p94
removes factors restricting the stability of proteins. If
these proteins are p94 substrates, structural changes in-
duced by proteolysis may make them more stable. On the
other hand, enzymes that promote degradation of these
proteins may be substrates for p94. Peptides with a fold-
change greater than 1.1 were subjected to manual in-
spection of their MS/MS spectra. Several peptides had re-
liable MS/MS spectra, but few represented parental pro-
teins with consistency. Thus, it was difficult to extract
proteins whose increase in abundance was dependent on
p94 protease activity. It is also possible that the protease
activity of p94 was not responsible for increasing the
Figure 6.Time course of in vitro translation of p94 and the μ-calpain large
subunit (μCL). In vitro transcribed RNA for rat p94 and human μCL were
translated with rabbit reticulocyte lysate and [35S]Met in the presence
(+inh.) or absence (-inh.) of 380 μg/mL leupeptin and E64, and sampled
at the indicated time (min). Samples are separated by SDS-PAGE, and ex-
posed to X-ray film (A) and an imaging plate. The radioactivities of 94-kDa
(open triangle) and 80-kDa (closed triangle) bands were quantified using
a Fujix Bioimage Analyzer, and plotted against the time of sampling (B).
Note that the scales for the Y-axes differ by a factor of 10.
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abundance of other proteins. Identification of such pro-
teins from COS7 cells was not pursued further and left for
the future investigation using different cell culture sys-
tem.
4 Concluding remarks
Quantitative comparison of proteomic data obtained from
COS7 cells expressing p94WT or p94CS was efficient in
surveying the change of protein abundance caused by
p94 protease activity. The advantages of this method over
the 2-DE method are not only simplicity and reproducibil-
ity, but also the ability to manipulate high molecular
weight proteins as evidenced by the results presented in
Table 2 for filamin-A and importin-7. Simultaneous iden-
tification and quantification by iTRAQTM analysis en-
abled us to detect potential p94 substrates that might
have been overlooked because of a lack of information
and/or analytical tools. Another advantage of the method-
ology described in this study is that it enables evaluation
of the consequences of proteolytic events from the abun-
dance of various proteolytic fragments from the same pro-
tein. As calpains have been implicated in modulation of
the function of substrate proteins, the abundance of the
parts of substrate proteins responsible for their functions
does not necessarily decrease upon proteolysis. The
quantitative nature and the unbiased sensitivity of the
method will be useful for identifying the fates of various
proteolytic products, which will complement other bio-
chemical and cell biological studies of proteolysis [46].
This methodology can be applied to all calpain species in
various differential analyses of pathological states, trans-
genic mice, and developmental stages.
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